Aiom
Anno I | Numero 7 | Novembre 2016
Comitato scientifico editoriale: Paolo A. Ascierto, Vanna Chiarion-Sileni
Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
 
 
Notizie dalla ricerca
 
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced …
Continua a leggere
 
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Inhibition of immune checkpoints using anti-programmed cell death-1 (PD-1) or anti cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibodies has revolutionized the management of patients with advanced-stage melanoma and is among the most promising treatment approaches for many other cancers. Use of CTLA-4 and PD-1 inhibitors, either as single agents, or in combination, has been approved by the US FDA for the treatment of metastatic …
Continua a leggere
 
Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma
With the wide use of anti-PD-1 therapy, an increasing number of patients progress under treatment. Combined immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies induces higher response rates as first-line treatment in comparison to single-agent therapy, however, with substantial toxicity since the combination of ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) induced 55% grade 3/4 treatment-related adverse events and treatment discontinuation rates of 39%. In this case …
Continua a leggere
 
Toxicity management of immunotherapy for patients with metastatic melanoma
Checkpoint inhibitors have revolutionized the treatment of patients with metastatic melanoma offering improved responses and significant survival benefit. These agents are now approved for the treatment of metastatic melanoma, squamous and non-squamous non-small cell lung cancer (NSCLC) and kidney cancer, while they are now being investigated in a range of other malignancies. In addition, another anti-PD-L1 monoclonal antibody (atezolizumab) was recently approved for …
Continua a leggere
 
Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma
Immune checkpoint inhibition with ipilimumab has revolutionized cancer immunotherapy and significantly improved outcomes of patients with advanced malignant melanoma. Local peripheral treatments (LPT), such as radiotherapy or electrochemotherapy, have been shown to modulate systemic immune responses, and preliminary data have raised the hypothesis that the combination of LPT with systemic immune checkpoint blockade might be beneficial. Clinical data from 127 consecutively …
Continua a leggere
 
Are there, or shall we discover, biomarkers to guide PD-1 inhibition?
Despite the recent success of PD-1/PD-L1-directed immunotherapy in a number of different malignancies, there are currently no effective biomarkers available to predict patient response to treatment. This question is particularly important because these immunotherapy agents are expensive and have significant toxicity profiles. Early data are emerging on biomarkers such as PD-L1 expression; however, it is clear that further studies are needed to identify alternative biomarkers and to improve …
Continua a leggere
 
Appuntamenti AIOM
 
4th International Conference 'Translational Research in Oncology'
Meldola (FC), 8 novembre 2016
Forlì, 9 – 11 novembre 2016
Informazioni disponibili sul sito dell'evento: www.fictro2016.it
 
Immuno-Oncologia: Stato dell'Arte e Update
Cagliari, 9 novembre 2016
Settima tappa del Progetto itinerante AIOM di Immuno-Oncologia. Evento riservato ai Soci AIOM Sardegna
Le eventuali spese di trasporto saranno rimborsate con apposito modulo consegnato direttamente in sede congressuale
 
Nuove frontiere diagnostico-terapeutiche nelle neoplasie polmonari, renali e nel melanoma
Varese, 12 novembre 2016
 
XXII Congresso Nazionale IMI – Intergruppo Melanoma Italiano
Multidisciplinarità e Integrazione Intorno al Paziente
Ragusa, 13 – 15 novembre 2016
 
Master Course IMI
Management del paziente con melanoma. Dalla ricerca alla terapia
Milano, 25 – 26 novembre 2016
 
First International Congress
Clinical Needs and Translational Research in Oncology
Reggio Emilia, 28 – 29 novembre 2016
 
Melanoma Bridge 2016
Napoli, 30 novembre – 3 dicembre 2016
 
Immunotherapy Bridge 2016
Napoli, 30 novembre 2016
 

Questi e altri appuntamenti si possono consultare sul sito AIOM
www.aiom.it
 

 
Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001
Per contattare la redazione e commentare le notizie clicca qui: redazione
Per consultare i numeri arretrati della newsletter clicca qui: archivio
Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI

Questo progetto è stato realizzato con il contributo di